Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share & Trends Report

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Size, Share & Trends Analysis Report By Animal Type (Production, Companion), By Service Type, By Synthesis Type, By Therapeutic Category, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68039-328-0
Number of Pages: 150
Format: Electronic (PDF)

Historical Range: 2018 - 2022
Industry: Healthcare

Market Segmentation

Veterinary API Manufacturing Service Type Outlook (Revenue, USD Million, 2018 - 2030)
- In House
- Contract Outsourcing
  - Contract Development
    - Preclinical Development
    - Clinical Development
  - Contract Manufacturing
Veterinary API Manufacturing Synthesis Type Outlook (Revenue, USD Million, 2018 - 2030)
- Chemical-based API
- Biological API
- HPAPI
Veterinary API Manufacturing Animal Type Outlook (Revenue, USD Million, 2018 - 2030)
- Production Animals
- Companion Animals
Veterinary API Manufacturing Therapeutic Category Outlook (Revenue, USD Million, 2018 - 2030)
- Antiparasitics
- Anti-infectives
- NSAIDs
- Others
Veterinary API Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
    - In House
    - Contract Outsourcing
      - Contract Development
        
        Preclinical Development
        
        Clinical Development
      - Contract Manufacturing
  - North America Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemical Based API
    - Biological API
    - HPAPI
  - North America Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
    - Production Animals
    - Companion Animals
  - North America Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
    - Antiparasitics
    - Anti-infectives
    - NSAIDs
    - Others
  - U.S.
    - U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - U.S. Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Canada
    - Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Canada Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Mexico
    - Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Mexico Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
- Europe
  - Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
    - In House
    - Contract Outsourcing
      - Contract Development
        
        Preclinical Development
        
        Clinical Development
      - Contract Manufacturing
  - Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemical Based API
    - Biological API
    - HPAPI
  - Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
    - Production Animals
    - Companion Animals
  - Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
    - Antiparasitics
    - Anti-infectives
    - NSAIDs
    - Others
  - Germany
    - Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Germany Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - UK
    - UK Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - UK Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - UK Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - UK Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - France
    - France Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - France Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - France Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - France Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Italy
    - Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Italy Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Spain
    - Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Spain Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Denmark
    - Denmark Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Denmark Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Denmark Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Denmark Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Norway
    - Norway Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Norway Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Norway Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Norway Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Sweden
    - Sweden Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Sweden Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Sweden Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Sweden Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Rest of Europe
    - Rest of Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Rest of Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Rest of Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Rest of Europe Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
- Asia Pacific
  - Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
    - In House
    - Contract Outsourcing
      - Contract Development
        
        Preclinical Development
        
        Clinical Development
      - Contract Manufacturing
  - Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemical Based API
    - Biological API
    - HPAPI
  - Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
    - Production Animals
    - Companion Animals
  - Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
    - Antiparasitics
    - Anti-infectives
    - NSAIDs
    - Others
  - Japan
    - Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Japan Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - China
    - China Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - China Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - China Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - China Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - India
    - India Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - India Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - India Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - India Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - South Korea
    - South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - South Korea Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Australia
    - Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Australia Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Thailand
    - Thailand Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Thailand Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Thailand Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Thailand Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Rest of Asia Pacific
    - Rest of Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Rest of Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Rest of Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Rest of Asia Pacific Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
- Latin America
  - Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
    - In House
    - Contract Outsourcing
      - Contract Development
        
        Preclinical Development
        
        Clinical Development
      - Contract Manufacturing
  - Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemical Based API
    - Biological API
    - HPAPI
  - Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
    - Production Animals
    - Companion Animals
  - Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
    - Antiparasitics
    - Anti-infectives
    - NSAIDs
    - Others
  - Brazil
    - Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Brazil Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Argentina
    - Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Argentina Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Rest of Latin America
    - Rest of Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Rest of Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Rest of Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Rest of Latin America Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
- Middle East & Africa
  - Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
    - In House
    - Contract Outsourcing
      - Contract Development
        
        Preclinical Development
        
        Clinical Development
      - Contract Manufacturing
  - Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemical Based API
    - Biological API
    - HPAPI
  - Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
    - Production Animals
    - Companion Animals
  - Middle East & Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
    - Antiparasitics
    - Anti-infectives
    - NSAIDs
    - Others
  - South Africa
    - South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - South Africa Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Saudi Arabia
    - Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Saudi Arabia Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Kuwait
    - Kuwait Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Kuwait Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Kuwait Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Kuwait Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - UAE
    - UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - UAE Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others
  - Rest of MEA
    - Rest of MEA Veterinary Active Pharmaceutical Ingredients Manufacturing Service Type Outlook (Revenue in USD Million, 2018 -2030)
      - In House
      - Contract Outsourcing
        
        Contract Development
        
        Preclinical Development
        
        Clinical Development
        
        Contract Manufacturing
    - Rest of MEA Veterinary Active Pharmaceutical Ingredients Manufacturing Synthesis Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemical Based API
      - Biological API
      - HPAPI
    - Rest of MEA Veterinary Active Pharmaceutical Ingredients Manufacturing Animal Type Outlook (Revenue in USD Million; 2018 - 2030)
      - Production Animals
      - Companion Animals
    - Rest of MEA Veterinary Active Pharmaceutical Ingredients Manufacturing Therapeutic Category Outlook (Revenue in USD Million; 2018 - 2030)
      - Antiparasitics
      - Anti-infectives
      - NSAIDs
      - Others

Veterinary Active Pharmaceutical Ingredients Manufacturing Market Dynamics

Driver: Increasing prevalence of zoonotic diseases

Zoonotic diseases, based on causative agents, are classified into bacterial, viral, and parasitic. These infections can spread through ticks, mosquitoes, and fleas or by direct contact with animals and can cause disorders such as rabies & Lyme disease. This is expected to drive the need for better treatment options for companion animals. Lyme disease is mostly caused by bacteria-carrying ticks. The WHO is engaged in various activities to address health risks at the animal–human ecosystem interface involving food-borne zoonoses, food safety, and antimicrobial resistance. Initiatives are being implemented by governments at the country & regional levels and the international level by WHO. The WHO collaborates with the World Organization for Animal Health, the Food and Agriculture Organization, National Ministries of Health, the World Bank, and UNSIC in a probe to take major actions for disease control.

Growing prevalence of zoonotic diseases is also driving the demand for drugs. This also boosts the demand for APIs for the production of these drugs. For instance, in 2021, according to CDC, 3 out of every 4 new or emerging infectious diseases in humans were animal borne, and more than 6 out of every 10 existing infectious diseases in humans can be transmitted from animals. Therefore, CDC undertakes initiatives in the U.S. and across the world to protect people from zoonotic diseases.

Driver: Increasing animal population and pet ownership

The increasing global animal population is driving the demand for manufacturing veterinary APIs used in the formulation of efficient drugs. Moreover, the growing adoption of animals as pets due to various associated health benefits, including decreased risk of cardiac arrhythmias, reduced anxiety, blood pressure stabilization, increased psychological stability, and overall improvement in wellbeing, drives market growth. For instance, according to the global animal health association, in the U.S., there are around 85 million dogs and 56 million cats. This highlights that families in the U.S., Europe, and China own around half a billion dogs & cats. The rising number of pet owners is expected to drive the overall market over the forecast period, which can be attributed to increase in the demand for treatment options. Pet owners belonging to millennial generations (26–41 years old) constitute the largest share among all age groups. As millennials and Generation Z (10–45 years old) consumers have reached adulthood, and they increasingly prefer owning pets compared to the prior generations, the pet population is growing. For instance, in 2021 according to American Pet Products Association (APPA) National Pet Owners Survey, approximately 32% of millennials owned pets. More than 67% of American households own at least one pet, and Americans collectively spend over USD 95 billion on their pets annually, according to APPA.

Restraint: Stringent government regulations

Manufacturing companies have to adhere to stringent safety & quality standards of every country where the API will be used. For instance, if an API is manufactured in China or India but is intended to be used in the U.S., it has to be inspected and licensed by the U.S. FDA. If it is to be used in Europe, it has to meet the regulations set by the European Medicines Agency. Furthermore, regular inspections conducted outside the manufacturing country prove to be difficult, with risks associated with contamination and counterfeiting. To eliminate these problems, the U.S. FDA increased its staff overseas. Due to this, countries such as India have gained a considerable foothold in the global market and have around 75 FDA-approved manufacturing facilities for API synthesis.

What Does This Report Include?

This section will provide insights into the contents included in this veterinary active pharmaceutical ingredients manufacturing market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Veterinary active pharmaceutical ingredients manufacturing market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Veterinary active pharmaceutical ingredients manufacturing market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.